These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23622648)

  • 1. Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.
    Sereno J; Parada B; Rodrigues-Santos P; Lopes PC; Carvalho E; Vala H; Teixeira-Lemos E; Alves R; Figueiredo A; Mota A; Teixeira F; Reis F
    Transplant Proc; 2013 Apr; 45(3):1149-56. PubMed ID: 23622648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine A-induced nephrotoxicity is ameliorated by dose reduction and conversion to sirolimus in the rat.
    Sereno J; Vala H; Nunes S; Rocha-Pereira P; Carvalho E; Alves R; Teixeira F; Reis F
    J Physiol Pharmacol; 2015 Apr; 66(2):285-99. PubMed ID: 25903959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine.
    Reis F; Parada B; Teixeira de Lemos E; Garrido P; Dias A; Piloto N; Baptista S; Sereno J; Eufrásio P; Costa E; Rocha-Pereira P; Santos-Silva A; Figueiredo A; Mota A; Teixeira F
    Transplant Proc; 2009 Apr; 41(3):868-73. PubMed ID: 19376375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
    Sereno J; Nunes S; Rodrigues-Santos P; Vala H; Rocha-Pereira P; Fernandes J; Santos-Silva A; Teixeira F; Reis F
    Biomed Res Int; 2014; 2014():576929. PubMed ID: 24971338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
    Wittmann S; Daniel C; Stief A; Vogelbacher R; Amann K; Hugo C
    Transplantation; 2009 May; 87(9):1290-9. PubMed ID: 19424027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taurine attenuates hypertension and renal dysfunction induced by cyclosporine A in rats.
    Hagar HH; El Etter E; Arafa M
    Clin Exp Pharmacol Physiol; 2006 Mar; 33(3):189-96. PubMed ID: 16487261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical results of sirolimus treatment in transplant models.
    Stepkowski SM
    Transplant Proc; 2003 May; 35(3 Suppl):219S-226S. PubMed ID: 12742499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
    Piao SG; Bae SK; Lim SW; Song JH; Chung BH; Choi BS; Yang CW
    Transplantation; 2012 Feb; 93(4):383-9. PubMed ID: 22267156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients.
    Joannides R; Etienne I; Iacob M; Hurault de Ligny B; Barbier S; Bellien J; Lebranchu Y; Thuillez C; Godin M
    Transpl Int; 2010 Nov; 23(11):1135-43. PubMed ID: 20536790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
    Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
    Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
    Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeic acid phenethyl ester protects against oxidative stress-related renal dysfunction in rats treated with cyclosporin A.
    Wongmekiat O; Gomonchareonsiri S; Thamprasert K
    Fundam Clin Pharmacol; 2011 Oct; 25(5):619-26. PubMed ID: 21077939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.